Findings from Children's Hospital in lymphoma in children reported

10-31-2006

A report, "No Influence of bcl-2, p53, and p21waf1 protein expression on the outcome of pediatric Hodgkin lymphomas," is newly published data in Journal of Pediatric Hematology. According to a study from Buenos Aires, Argentina, "In Argentina, lymphomas account for 13.6% of all pediatric tumors and 47% of them are Hodgkin lymphoma. Previous studies of lymphoma series have reported the expression of apoptotic and cell cycle proteins."

"Our aim was to study these markers in our pediatric patients and correlate them with their outcome. Immunohistochemical staining with monoclonal antibodies anti-p53, bcl-2, p21, and mdm2 were performed on formalin-fixed paraffin-embedded Hodgkin lymphoma lymph node biopsies from 54 pediatric patients. The analyzed oncogenes p53, bcl-2, p21, and mdm2 exhibited 81%, 44%, 76%, and 90% positive staining, respectively. The most prevalent p53/p21 expression pattern was p53+/p21+, in 57% of cases, whereas concerning p53/mdm2 expression pattern p53+/mdm2+ was observed in 61% of cases. We failed to find any statistically significant correlation between oncogene expression and patient's survival. It seems that p53 plays an important role in lymphomagenesis in our studied population, because it is overexpressed in 81% of Hodgkin lymphoma cases and in more than 50% of cases, it might be able to activate its cellular effectors," wrote P. Chabay and colleagues, Children's Hospital.

The researchers concluded: "Bcl-2 staining observed in 44% of our cases could represent a failure in bcl-2 down-regulation that leads to a rescue event in defective germinal center B-cells, that allows them to develop into Reed-Sternberg and Hodgkin cells."

Chabay and colleagues published the results of their research in the Journal of Pediatric Hematology (No Influence of bcl-2, p53, and p21waf1 protein expression on the outcome of pediatric Hodgkin lymphomas. Journal of Pediatric Hematology, 2006;28(9):552-8).

For additional information, contact P. Chabay, Ricardo Gutierrez Children's Hospital, Virology Laboratory, Buenos Aires, Argentina.

The publisher of the Journal of Pediatric Hematology can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St., Philadelphia, PA 19106-3621, USA.

Keywords: Argentina, Buenos Aires, Hematology, Lymphoma, Oncology, Pediatric Hematology.

This article was prepared by Hematology Week editors from staff and other reports. Copyright 2006, Hematology Week via NewsRx.com.



Related Diseases: Hodgkin Lymphoma
Related Keywords: Bcl-2, P53
Related Glossary Terms: Hodgkin Lymphoma
 
RECENT NEWS
 
Acute Lymphocytic Leukemia (ALL)
Best and brightest leukemia researchers receive $1-million from Cole Foundation
Microenvironment a main driver of aggressive multi-lineage leukemia disease type
Researchers Expand Natural Killer Cells In Cord Blood To Fight Leukemia
New drug combination brings 1-2 punch against acute leukemia
ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting
Acute Myeloid Leukemia (AML)
Radiation Therapy for Prostate Cancer Increases Incidence of AML
Gene mutation improves leukemia drug's effect
EpiCept Releases New Ceplene AML Data Demonstrating Leukemia Free Survival as Predictor of Improved Overall Survival
Best and brightest leukemia researchers receive $1-million from Cole Foundation
Amyloidosis
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
STEM CELL TRANSPLANTATION PROCEDURE RESULTS IN LONG-TERM SURVIVAL FOR AMYLOIDOSIS PATIENTS
Neurochem receives approvable letter for eprodisate (KIACTA) for treatment of AA amyloidosis
Neurochem, Inc. (NRMX) Receives Approvable Letter for Eprodisate (KIACTA(TM)) for Treatment of AA Amyloidosis; FDA Asks for More Data
STEM CELL PROCEDURE SUCCESSFULLY TREATS AMYLOIDOSIS PATIENTS
Aplastic Anemia
Blood Stem Cells Originate in the Placenta
Stem Cells from a Person's Own Umbilical Cord Effective Treatment For Life-Threatening Blood Disease, Study Data Show
Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Decision Fails Patients with Transfusion-Dependent Anemia
Chronic Lymphocytic Leukemia (CLL)
Patients with Lymphoma and CLL Are at Increased Risk of Lung Cancer
Best and brightest leukemia researchers receive $1-million from Cole Foundation
Microenvironment a main driver of aggressive multi-lineage leukemia disease type
New lymphoma therapies targets diverse and difficult cancer
Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
Chronic Myeloid Leukemia (CML)
Activation of LYN kinase is associated with imatinib-resistance in CML patients
CHEMGENEX'S OMACETAXINE DEMONSTRATES ACTIVITY IN CML PATIENTS WHO HAVE FAILED THERAPY WITH MULTIPLE TYROSINE KINASE INHIBITORS
Best and brightest leukemia researchers receive $1-million from Cole Foundation
Microenvironment a main driver of aggressive multi-lineage leukemia disease type
Combination of two novel anti-cancer agents may help fight CML resistant to current therapy
Hodgkin Lymphoma
Patients with Lymphoma and CLL Are at Increased Risk of Lung Cancer
Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model
Gloucester Presents Positive Results From Phase IIb Lymphoma Trial
Mile High Amazing Race Downtown Denver 5/17
Stem Cell Transplant Procedures Vary Throughout the World
Multiple Myeloma
Does a 10-year 10% Continuous Complete Remission Rate for Myeloma Patients Suggest Cure?
Thalidomide Plus Dexamethasone: Improved Primary Myeloma Therapy
Bone Pain Can Be A Sign Of Myeloma - Patients And Doctors Join Forces To Raise Awareness Of Early Myeloma Diagnosis
Lenalidomide raises clot risk in multiple myeloma patients
Immunomedics, Inc. (IMMU)'s Milatuzumab receives FDA orphan drug designation
Myelodysplastic Syndrome (MDS)
Xanthus Presents Updated Xanafide Phase 2 Data Showing Durable Complete Remissions in Secondary AML
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine (VNP40101M) in Combination with Cytarabine
ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting
Scoring system identifies MDS patients who have low-risk disease but a poor prognosis
Seattle Genetics Initiates Phase IIb Clinical Trial of SGN-33 in Combination with Chemotherapy for Acute Myeloid Leukemia
Non-Hodgkin Lymphoma (NHL)
Patients with Lymphoma and CLL Are at Increased Risk of Lung Cancer
Every patient is unique: Individualized therapies for non-Hodgkin's lymphoma
Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model
Xencor to Present New Data from Anti-CD19 Antibody Program at ASCO
Data from Phase II Clinical Trial of Galiximab in Combination with Rituximab in Patients with Previously Untreated Follicular Lymphoma Presented at International Conference on Malignant Lymphoma
Testicular Cancer
Single Dose of Carboplatin as Effective as Radiation Therapy for Testicular Cancer
Single Dose of Chemotherapy as Effective as Weeks of Radiation Therapy for Testicular Cancer
Drug avoids radiation for early testicular cancer
Polymorphism Reduces Benefit of Bleomycin in Testicular Cancer
Increased Life Expectancy Seen For Patients With Advanced Colorectal, Ovarian and Testicular Cancer